Drugs / YH12852
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03381703 | Mar 2017 | constipation disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01870674 | Aug 2013 → Apr 2015 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02538367 | Aug 2015 → Sep 2016 | constipation disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02567578 | Oct 2015 → Mar 2017 | dyspepsia | Yuhan Corporation | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-08-20 | Processa Pharmaceuticals | PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS processapharmaceuticals.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH12852 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02567578 ↗ |
| Route | Oral | “YH12852 After Oral Administration” NCT01870674 ↗ |